Business · 09/10/2026Updated: 10/15/2026 · 1 min read
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZANVASTRO (Zilganersen)
Summary
The Food and Drug Administration (FDA) is issuing a priority review voucher to the sponsor of a rare pediatric disease product application for ZANVASTRO (Zilganersen).
Original source language: Federal Register — Health and Human ServicesOpen original release →